

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* <u>Van Strydonck, Gerald E.</u>			2. Issuer Name and Ticker or Trading Symbol <u>VACCINEX, INC. [VCNX]</u>			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner Officer (give title below) Other (specify below)		
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) <u>12/08/2023</u>			6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person		
C/O VACCINEX, INC. 1895 MOUNT HOPE AVENUE			4. If Amendment, Date of Original Filed (Month/Day/Year)			Rule 10b5-1(c) Transaction Indication <input type="checkbox"/> Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.		
(Street)	(City)	(State)	(Zip)					
ROCHESTER	NY		14620					

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	12/08/2023		S		1,334	D	\$0.67	3,149	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Stock Option (Right to Buy)	\$204							(1)	09/15/2027	Common Stock	426	426	D		
Stock Option (Right to Buy)	\$78.9							(1)	03/30/2029	Common Stock	166	166	D		
Stock Option (Right to Buy)	\$116.7								05/15/2020	(2)	Common Stock	514	514	D	
Stock Option (Right to Buy)	\$82.8							(1)	06/29/2029	Common Stock	159	159	D		
Stock Option (Right to Buy)	\$107.55							(1)	09/27/2029	Common Stock	123	123	D		
Stock Option (Right to Buy)	\$72.75							(1)	12/28/2029	Common Stock	182	182	D		
Stock Option (Right to Buy)	\$59.25								05/14/2021	(3)	Common Stock	1,045	1,045	D	
Stock Option (Right to Buy)	\$32.25								05/11/2022	(4)	Common Stock	1,905	1,905	D	
Stock Option (Right to Buy)	\$16.8								05/12/2023	(5)	Common Stock	3,550	3,550	D	
Stock Option (Right to Buy)	\$6.15								05/11/2024	(6)	Common Stock	9,589	9,589	D	

Explanation of Responses:

1. Exercisable in full as of the date of this report.
2. This option expires on May 14, 2029 or five years following retirement or cessation of services, whichever occurs first.
3. This option expires on May 12, 2030 or five years following retirement or cessation of services, whichever occurs first.
4. This option expires on May 9, 2031 or five years following retirement or cessation of services, whichever occurs first.
5. This option expires on May 9, 2032 or five years following retirement or cessation of services, whichever occurs first.
6. This option expires on May 8, 2033 or five years following retirement or cessation of services, whichever occurs first.

Remarks:

On September 25, 2023, Vaccinex, Inc. effected a 1-for-15 reverse stock split (the "Reverse Stock Split"). All figures in this Form 4 reflect the Reverse Stock Split.

/s/ Scott E. Royer, Attorney-in-Fact for Gerald Van Strydonck 12/12/2023

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.